Borer Denton & Associates’s AbbVie ABBV Stock Holding History

Borer Denton & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.4M	Sell	57,044 -880	-2%	-$195K	4.43%	6
2025 Q4	$13.2M	Sell	57,924 -305	-0.5%	-$69.5K	4.46%	5
2025 Q3	$13.5M	Buy	58,229 +245	+0.4%	+$49.9K	4.45%	7
2025 Q2	$10.8M	Sell	57,984 -25	-0%	-$4.65K	3.74%	8
2025 Q1	$12.2M	Sell	58,009 -1,225	-2%	-$238K	4.3%	7
2024 Q4	$10.5M	Buy	59,234 +920	+2%	+$169K	3.66%	7
2024 Q3	$11.5M	Buy	58,314 +1,405	+2%	+$262K	3.93%	7
2024 Q2	$9.76M	Sell	56,909 -1,800	-3%	-$298K	3.54%	8
2024 Q1	$10.7M	Buy	58,709 +694	+1%	+$120K	3.78%	8
2023 Q4	$8.99M	Hold	58,015	–	–	3.44%	12
2023 Q3	$8.65M	Hold	58,015	–	–	3.57%	12
2023 Q2	$7.82M	Hold	58,015	–	–	3.08%	14
2023 Q1	$9.25M	Buy	58,015 +503	+0.9%	+$76.9K	3.84%	11
2022 Q4	$9.29M	Buy	57,512 +362	+0.6%	+$55.5K	4.12%	7
2022 Q3	$7.67M	Sell	57,150 -102	-0.2%	-$14.6K	3.82%	9
2022 Q2	$8.77M	Sell	57,252 -100	-0.2%	-$15.3K	4.23%	8
2022 Q1	$9.3M	Buy	+57,352	New	+$8.33M	3.9%	8

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Borer Denton & Associates's ABBV Position: Q1 2026 in Review

Borer Denton & Associates reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $195K and leaving 57,044 shares worth $12.4M. The position accounts for 4.43% of the portfolio, ranked #6.

Borer Denton & Associates first reported a position in ABBV in Q1 2022 and has held it in 17 quarters since. The position peaked at $13.5M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Borer Denton & Associates held 57,044 shares of AbbVie worth $12.4M as of Q1 2026.
Borer Denton & Associates sold 880 AbbVie shares in Q1 2026, an estimated $195K.
AbbVie made up 4.43% of Borer Denton & Associates's portfolio in Q1 2026, its #6 holding.
Borer Denton & Associates first reported a position in AbbVie in Q1 2022 and has held it in 17 quarters since.
Borer Denton & Associates's AbbVie position peaked at $13.5M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Borer Denton & Associates's 13F filing for Q1 2026, filed 12 May 2026.